Rationale use of drugs in pregnancy induced hypertension at a tertiary care hospital


  • Dwajani S. Department of Pharmacology, Central Research Lab, Rajarajeswari Medical College and Hospital, Bangalore, Karnataka, India
  • Samhitha Kulkarni Rajarajeswari Medical College and Hospital, Bangalore, Karnataka, India
  • Andrea S. Vincent Rajarajeswari Medical College and Hospital, Bangalore, Karnataka, India
  • Sanjana B. M. Rajarajeswari Medical College and Hospital, Bangalore, Karnataka, India




Pregnant women, Hypertension, Preeclampsia, Rationale drug use


Background: Pregnancy induced hypertension known as preeclampsia is considered to be the second cause of death next to anaemia. There are significant sources of maternal and foetal mortality and morbidity. Antihypertensive medication reduces the progression of the course of hypertensive disorders. However, its effect on the outcomes of pregnancy may include development of preeclampsia, preterm delivery, foetal /neonatal demise, IUGR, low birth weight. Whether such associations are casual or confounded is unknown. Hence, we intended to study the rationale use of drugs in pregnancy induced hypertensive patients.

Methods: Patients diagnosed with hypertensive disorders in pregnancy were recruited. Pregnant women in the age group of 18-45 years who consented to participate were included. Non pregnant women and women with PCOD, depression and on any medications were excluded. Details on drug treatment, type of drugs, combination, dose, dosage and duration were noted.

Results: 105 patients were enrolled. 51% belonged to 18-25 years. 98% mothers received monotherapy and 2% received dual therapy. Labetalol was the most commonly prescribed drug. 50% of the patients received a combination of Nifedipine and Methyldopa while another 50% received Nifedipine with Labetalol. The outcome of new born babies born in mothers receiving antihypertensive drugs had complications of low birth weight and malformations. The dose of the medications prescribed was well within the range.

Conclusions: Proper counselling to the patients regarding life style management, regular follow ups and monitoring of blood pressure is important to understand, resolve the burden and complication.


Barrilleaux PS, Martin JN. Hypertensive therapy during pregnancy. Clin Obstet Gynecol. 2002;45(1): 22-34.

Dutta DC, Hypertensive disorders in pregnancy. In: text book of obstetrics including perinatology and contraception. 6th ed. Calcutta: New central book agency; 2004:221-42.

Doddamani GB, Doddamani UG. Perinatal outcome in pre-eclampsia: a prospective study. Sch J App Med Sci. 2014;2(1):291-3.

Dukkitt K, Harrington D. Risk factors for preeclampsia antenatal booking: Systemic review of controlled studies. BMJ. 2005;330:565-7.

Alvarez NR, Marin R. Severe maternal complications associated with pre-eclampsia: an almost forgotten pathology? Nefrologia. 2001;21:565-73.

Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183:S-S22.

Abalos E, Duley L, Steyen DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007:CD002252.

De Sweit M. Maternal blood pressure and birth weight. Lancet. 2000;355:81-2.

Tabacova S, Kimmel CA, Wall K, Hansen D. Atenolol toxicity: animal to human comparisons. Birth Defects Res Part A Clin Mol Teratol. 2003,67: 181-92.

Senthil S, Greeshma R, Indu PV, Anaith K, Ganeshan GV. A prospective observational study of drug utilization pattern of pregnancy induced hypertension and complication of pregnancy induced hypertension in pregnant women and newborn in secondary care hospital Tirupur. Int J Recent Sci Res. 2020;11(1A): 36813-18.

Swati S. Hypertensive disorders in pregnancy among pregnant women in a Nigerian teaching hospital. West Afr J Med. 2012;21:74-6.

Chung Y. The 2011 survey on hypertensive disorders of pregnancy in china: prevalence, risk factors, complications, pregnancy and perinatal outcomes. J PLOS One. 2014;9(6):1-10.

Kirsten D, Deborah H. Risk factors for preeclampsia at antenatal booking: systemic review of controlled studies. BMJ. 2005;5:330-65.

Owiredu WKBK, Ahenkorah L, Turpin CA, Amidu N, Lang EF. Putative risk factors of pregnancy induced hypertension among Ghanaian pregnant women. J Med Biomed Sci. 2012;1(3):62-76.

Braunthal S, Brateanu A. Hypertension in pregnancy: Pathophysiology and treatment. SAGE Open Med. 2019;7:1-15.

Bangal VB, Giri PA, Mahajan AS. Maternal and fetal outcome in pregnancy induced hypertension; a study from rural tertiary care teaching hospital in India. Int J Biomed Res. 2012;2:595-9.

Kumar NT. Prescription pattern of drugs in pregnancy induced hypertension in tertiary care hospital. Int J Basic Clin Pharmacol. 2013;2(6):783-87.

Archana T. Appraisement of preponderance and risk factors of gestational hypertension in a tertiary care referral hospital. Eur J Pharma Med Res. 2017;4(9): 361-79.




How to Cite

S., D., Kulkarni , S., Vincent , A. S., & B. M., S. (2023). Rationale use of drugs in pregnancy induced hypertension at a tertiary care hospital . International Journal of Basic & Clinical Pharmacology, 12(5), 722–725. https://doi.org/10.18203/2319-2003.ijbcp20232570



Original Research Articles